Strategic Wealth Investment Group LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 32.5% in the fourth quarter, Holdings Channel reports. The firm owned 12,318 shares of the company’s stock after selling 5,937 shares during the period. Eli Lilly and Company comprises approximately 1.6% of Strategic Wealth Investment Group LLC’s holdings, making the stock its 23rd biggest position. Strategic Wealth Investment Group LLC’s holdings in Eli Lilly and Company were worth $13,238,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in LLY. Brighton Jones LLC grew its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. grew its position in shares of Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $749,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Stock Performance
NYSE LLY opened at $1,133.15 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,166.29. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market capitalization of $1.07 trillion, a P/E ratio of 40.25, a P/E/G ratio of 1.24 and a beta of 0.53. The company has a fifty day moving average of $974.59 and a 200-day moving average of $1,013.04.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.
Wall Street Analysts Forecast Growth
LLY has been the subject of a number of research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Barclays lifted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Finally, Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.
Read Our Latest Stock Analysis on LLY
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
- Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
- Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
- Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
- Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
- Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
- Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
